Market Overview

Oncolytics Announces First Stage of Metastatic Melanoma Phase 2 Trial Meets Primary Endpoint

Share:
Related ONCY
Oncolytics Biotech Announces Phase 1b Study in Advanced Pancreatic Cancer is Now Active
Oncolytics Biotech Collaborators to Present Survival Data from REO 016 Study in NCLC at IASLC

Oncolytics Biotech Inc. ("Oncolytics")
(NASDAQ: ONCY) today announced preliminary results from its
U.S. Phase 2 clinical trial in patients with metastatic melanoma using
intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel (REO 020). The Principal
Investigator is Dr. Devalingam Mahalingam, M.D., Ph.D., MRCP(UK),
MRCP(I), clinical investigator in GI/thoracic…Oncolytics Biotech Inc. ("Oncolytics")
(TSX:ONC, NASDAQ:ONCY) today announced preliminary results from its
U.S. Phase 2 clinical trial in patients with metastatic melanoma using
intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel (REO 020). The Principal
Investigator is Dr. Devalingam Mahalingam, M.D., Ph.D., MRCP(UK),
MRCP(I), clinical investigator in GI/thoracic oncology and drug
development at the Cancer Therapy & Research Center at the University
of Texas Health Science Center (CTRC).

Eligible patients include those with metastatic malignant melanoma who
have failed one or more prior therapies or those not considered a
candidate for standard first line therapy. The primary objective of the
Phase 2 trial is to assess the antitumour effect of the treatment
regimen in the study population in terms of objective response rates.
The secondary objectives are to assess progression-free survival and
overall survival for the treatment regimen; the disease control rate
(complete response (CR) plus partial response (PR) plus stable disease
(SD)) and duration, and to assess the safety and tolerability of the
treatment regimen in the study population.

The study is a two stage design. Up to 18 evaluable patients with
metastatic melanoma were to be treated in the first stage. If

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (ONCY)

View Comments and Join the Discussion!